Aditxt Divests Pearsanta for Contingent Royalties and Milestones
ADTX sits 22% above its 52-week low of $0.002.
Summary
Aditxt sold its Pearsanta subsidiary to MDNA Holdings for future royalty and milestone payments, with no upfront cash.
Key Events · M&A and Partnerships · ADTX
-
Pearsanta Divestiture
On August 12, 2026, Aditxt sold substantially all outstanding shares of Pearsanta, Inc. to MDNA Holdings Inc., with no upfront cash consideration.
-
Royalty Structure
Pearsanta will pay Aditxt a 2.5% royalty on Net Revenue, capped at $2.5 million aggregate, beginning upon first commercial sale and ending after 10 years or cap reached.
-
Milestone Payments
Aditxt will receive $250,000 if Pearsanta completes a financing of $10 million or more, and another $250,000 upon an IPO, reverse merger, or change of control.
-
Liability Transfer
Buyer assumed Pearsanta's liabilities reflected in the closing statement, excluding intercompany balances and certain retained liabilities.
Analysis · ADTX · Life Sciences
Aditxt divested its majority-owned subsidiary Pearsanta to MDNA Holdings, receiving no upfront cash but retaining a 2.5% royalty on future net revenue capped at $2.5 million, plus milestone payments tied to financing and liquidity events. For a company with a market cap near $2.2 million and severe financial distress, this transaction removes a subsidiary and its liabilities from the balance sheet while providing contingent upside. The lack of upfront consideration reflects the company's weak negotiating position, but the deal may help simplify operations and reduce cash burn.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADTX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.00 to $28,801.19. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.